CIOMS and ICH Initiatives in Pharmacovigilance and Risk Management: Overview and Implications

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.8, 2004-01, pp. : 509-517

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacovigilance during the Pre-Approval Phases: An Evolving Pharmaceutical Industry Model In Response To ICH E2E, CIOMS VI, FDA and EMEA/CHMP Risk-Management Guidelines

By Hartford Craig G.

Drug Safety, Vol. 29, Iss. 8, 2006-01 ,pp. : 657-673

Adis International

Access to resources Recommend Favorite

Data Quality Management in Pharmacovigilance

By Lindquist Marie

Drug Safety, Vol. 27, Iss. 12, 2004-01 ,pp. : 857-870

Adis International

Access to resources Recommend Favorite

ABSTRACTS: 9th ISoP Annual Meeting `From Pharmacovigilance to Risk Management', Reims, France, 6-9 October 2009

Drug Safety, Vol. 32, Iss. 10, 2009-10 ,pp. : 875-993

Adis International

Access to resources Recommend Favorite

Using MedDRA: Implications for Risk Management

By Brown E.G.

Drug Safety, Vol. 27, Iss. 8, 2004-01 ,pp. : 591-602

Adis International

Access to resources Recommend Favorite

The Risk of Stroke in Patients with Migraine and Implications for Migraine Management

By Tietjen Gretchen E.

CNS Drugs, Vol. 19, Iss. 8, 2005-01 ,pp. : 683-692

Adis International

Access to resources Recommend Favorite